Notox Technologies (NTOX) 10-Q 19 Apr 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Feb. 28, 2019	Apr. 19, 2019
Document And Entity Information
Entity Registrant Name	NOTOX TECHNOLOGIES CORP.
Entity Central Index Key	0000844538
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 28, 2019
Current Fiscal Year End Date	--08-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		57,545,343
Trading Symbol	NTOX
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - CAD ($)	Feb. 28, 2019	Aug. 31, 2018
Current assets:
Cash	$ 103,318	$ 5,664
Amounts receivable	4,045	6
Sales tax receivable	72,295	72,295
Prepaid expenses	15,002	24,048
Total current assets	194,660	102,013
Patents, net	4	4
License agreement, net (Note 5)	1,031,066	1,124,799
Total assets	1,225,730	1,226,816
Current liabilities:
Accounts payable and accrued liabilities (Note 6)	1,876,870	1,582,691
Advances from related parties/shareholders (Notes 7 and 8)	565,732	477,509
License assignment fee and accrued interest payable (Note 9)	1,000,758	882,257
Stock purchase warrants (Note 11)	197,626	353,517
Stock subscribed		10,000
Total current liabilities	3,640,986	3,305,974
Due to the Clinic (Note 5)	237,341	227,707
Total liabilities	3,878,327	3,533,681
Stockholders' deficiency (Note 11):
Common stock	1,018,256	1,018,256
Additional paid-in capital	8,458,365	8,458,365
Shares to be issued	119,890
Deficit	(12,249,108)	(11,783,486)
Total stockholders' deficiency	(2,652,597)	(2,306,865)
Total liabilities and stockholders' deficiency	$ 1,225,730	$ 1,226,816

Condensed Consolidated Statemen

Condensed Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - CAD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018	Feb. 28, 2019	Feb. 28, 2018
Revenue:
Sales
Production costs:
Amortization - license agreement (Note 5)	46,866	46,866	93,733	93,733
Consulting fees - production		585		1,155
Depreciation		1,710		3,420
Patenting costs - the Clinic		10,175	7,813	10,175
Total production costs	46,866	59,336	101,546	108,483
Gross loss	(46,866)	(59,336)	(101,546)	(108,483)
General and administration:
Consulting fees - management (Note 7)	235	118,076	81,999	235,766
Depreciation		(2,820)
Interest on advances from related parties/shareholders (Note 7)	3,136	8,089	5,956	8,089
Interest on license assignment fee payable (Note 9)	53,595		106,495
Loss (gain) on foreign exchange	225,379	(5,437)	263,137	31,110
Marketing	124		124	247
Office and miscellaneous	449	2,614	813	5,094
Patent maintenance fees		1,394		1,394
Professional fees	11,854	13,000	32,334	29,396
Rent	5,530	7,439	10,780	13,139
Travel and entertainment	435	1,181	1,569	2,426
Trust and filing fees	6,185	5,936	14,979	12,075
Total general and administration	306,922	149,472	518,186	338,736
Loss before other items and income taxes	(353,788)	(208,808)	(619,732)	(447,219)
Other items:
Other income	2,800		2,800
Discounts received	4,172		4,172
Gain on revaluation of stock purchase warrants (Note 11)	4,326	75,549	46,083	102,616
Gain on expiration of stock purchase warrants (Note 11)			109,808
Write-down of amounts receivable		(13,000)	(8,753)	(18,746)
Loss before income taxes	(342,490)	(146,259)	(465,622)	(363,349)
Income taxes
Net loss and comprehensive loss	$ (342,490)	$ (146,259)	$ (465,622)	$ (363,349)
Net loss per share - basic and diluted	$ (0.01)	$ 0	$ (0.01)	$ (0.01)
Weighted-average number of shares outstanding	57,539,763	57,507,318	57,539,763	57,507,318

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - CAD ($)	3 Months Ended				6 Months Ended
	Feb. 28, 2019	Nov. 30, 2018	Feb. 28, 2018	Nov. 30, 2017	Feb. 28, 2019	Aug. 31, 2018	Feb. 28, 2018
Cash Flows Used In Operating Activities
Net loss	$ (342,490)	$ (123,132)	$ (146,259)	$ (217,090)	$ (465,622)	$ (447,476)	$ (363,349)
Adjustments to reconcile net loss to net cash provided by operating activities:
Amortization - license agreement	46,866		46,866		93,733		93,733
Depreciation							3,420
Discount received and other income					(6,972)
Unrealized foreign exchange on license assignment fee payable							14,879
Unrealized foreign exchange on license assignment fee payable interest payable					118,501
Unrealized foreign exchange on due to the Clinic					9,634		4,511
Write-down of amounts receivable					8,753		18,746
Gain on revaluation of stock purchase warrants	(4,326)		(75,549)		(46,083)		(102,616)
Gain on expiration of stock purchase warrants					(109,808)
Changes in assets and liabilities:
Amounts receivable					(4,039)		(19,879)
Prepaid expenses					9,046		13,410
Accounts payable and accrued liabilities					292,398		246,420
Due to the Clinic							10,175
Interest accrued on advances from related parties/shareholders							8,089
Net cash used in operating activities					(100,459)		(72,460)
Cash Flows Provided By (Used In) Financing Activities
Shares to be issued					104,890
Stock issue costs							(6,435)
Advances from related parties/shareholders					88,223		46,000
Proceeds from exercise of warrants					5,000
Stock subscriptions received							10,000
Net cash provided by (used in) financing activities					198,113		(49,565)
Increase (decrease) in cash during the period					97,654		(22,895)
Cash, beginning of period		$ 5,664		$ 63,144	5,664	40,249	63,144
Cash, end of period	$ 103,318		$ 40,249		103,318	$ 5,664	40,249
Supplementary Information:
Interest paid
Taxes paid

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - CAD ($)	3 Months Ended				6 Months Ended			12 Months Ended
	Feb. 28, 2019	Nov. 30, 2018	Feb. 28, 2018	Nov. 30, 2017	Feb. 28, 2019	Aug. 31, 2018	Feb. 28, 2018	Aug. 31, 2017
Common Stock [Member]
Balance	$ 1,018,256	$ 1,018,256	$ 1,018,256	$ 526,182	$ 1,018,256	$ 1,018,256	$ 526,182
Balance, shares	57,532,843	57,532,843	57,532,843	56,892,843	57,532,843	57,532,843	56,892,843
Stock issued for cash				$ 491,041
Stock issued for cash, shares				630,000
Stock issue costs - cash				$ (6,435)
Stock issue costs - finder's warrants				(2,581)
Warrants exercised				$ 10,049
Warrants exercised, shares				10,000
Shares to be issued								$ 8,000
Shares to be issued, shares					5,000
Net loss
Balance	$ 1,018,256	$ 1,018,256	$ 1,018,256	$ 1,018,256	$ 1,018,256	$ 1,018,256	$ 1,018,256	$ 526,182
Balance, shares	57,532,843	57,532,843	57,532,843	57,532,843	57,532,843	57,532,843	57,532,843	56,892,843
Shared to be Issued [Member]
Balance	$ 10,000
Stock issued for cash
Stock issue costs - cash
Stock issue costs - finder's warrants
Warrants exercised	$ 5,000	10,000
Warrants exercised, shares
Shares to be issued	$ 104,890				$ (119,890)
Shares to be issued, shares					98,750
Net loss
Balance	119,890	10,000			$ 119,890
Additional Paid-in Capital [Member]
Balance	8,458,365	8,458,365	8,458,365	8,460,414	8,458,365	8,458,365	8,460,414
Stock issued for cash
Stock issue costs - cash
Stock issue costs - finder's warrants
Warrants exercised				(2,049)
Shares to be issued
Net loss
Balance	8,458,365	8,458,365	8,458,365	8,458,365	8,458,365	8,458,365	8,458,365	8,460,414
Deficit [Member]
Balance	(11,906,618)	(11,783,486)	(11,189,751)	(10,972,661)	(11,783,486)	(11,336,010)	(10,972,661)
Stock issued for cash
Stock issue costs - cash
Stock issue costs - finder's warrants
Warrants exercised
Shares to be issued
Net loss	(342,490)	(123,132)	(146,259)	(217,090)		(447,476)
Balance	(12,249,108)	(11,906,618)	(11,336,010)	(11,189,751)	(12,249,108)	(11,783,486)	(11,336,010)	(10,972,661)
Balance	(2,419,997)	(2,306,865)	(1,713,130)	(1,986,065)	$ (2,306,865)	(1,859,389)	(1,986,065)
Stock issued for cash				491,041
Stock issue costs - cash				(6,435)
Stock issue costs - finder's warrants				(2,581)
Warrants exercised	5,000	10,000		8,000
Shares to be issued	104,890
Shares to be issued, shares
Net loss	(342,490)	(123,132)	(146,259)	(217,090)	$ (465,622)	(447,476)	(363,349)
Balance	$ (2,652,597)	$ (2,419,997)	$ (1,859,389)	$ (1,713,130)	$ (2,652,597)	$ (2,306,865)	$ (1,859,389)	$ (1,986,065)

Company Overview and Basis of P

Company Overview and Basis of Presentation	6 Months Ended
	Feb. 28, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company Overview and Basis of Presentation	1. Company Overview and Basis of Presentation Nature and History of Operations Notox Technologies Corp. (formerly Tropic International Inc.) (the “Company”) was incorporated under the laws of the state of Nevada on October 29, 2007 under the name Rockford Minerals Inc. On June 28, 2013, the Company completed a reverse takeover transaction with Tropic Spa Inc. (“TSI”), a private Ontario corporation that manufactured and sold Home Mist Tanning units that deliver a full-body application. As a result of this transaction, the Company became a holding company operating through TSI. On December 6, 2013, the Company changed its name to Tropic International Inc. as a result of a merger with a wholly-owned subsidiary incorporated solely to effect the name change. On November 19, 2018, the Company again changed its name to Notox Technologies Corp. On June 13, 2016, the Company completed an asset acquisition transaction with Notox Bioscience Inc. (“Notox”), a private Nevada corporation incorporated on May 31, 2016 for the purpose of acquiring 100% of the right, title and interest in and to an exclusive license agreement (the “License Agreement”) with The Cleveland Clinic Foundation (the “Clinic”), an Ohio not-for-profit corporation. As a result of this transaction, the Company is a holding company operating through both TSI and Notox. As reflected in the accompanying condensed consolidated financial statements, the Company has a deficit of $12,249,108 (August 31, 2018 - $11,783,486) since inception, a working capital deficiency of $3,446,326 (August 31, 2018 - $3,203,961) and a stockholders’ deficiency of $2,652,597 (August 31, 2018 - $2,306,865). This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on its ability to raise additional capital and to implement its business plan. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management has evaluated the Company’s ability to continue as a going concern by assessing its ability to meet its obligations as they become due within one year from the date of issue of the financial statements. Management’s assessment included the following factors: ● The Company’s financial condition as at the date of issue of the financial statements; ● The Company’s actual or anticipated conditional and unconditional obligations due within one year from the date of issue of the financial statements; ● The funds necessary to maintain the Company’s operations considering its current financial condition, obligations and other expected cash flows; and ● Other conditions and events that may affect the Company’s ability to meet its obligations within one year from the date of issue of the financial statements. The Company’s operating expenses are estimated to be approximately $100,000 per year. As at February 28, 2019, the Company’s current cash liabilities total $3,443,360 (August 31, 2018 - $2,942,000). Of this amount, accounts payable and accrued liabilities are $1,876,870, advances from related parties/shareholders are $565,732 and license assignment fee and accrued interest payable $1,000,758 – is payable to related parties and/or major shareholders who have not and will not require payment until such time as sufficient cash flow is available. The Company’s CEO and President have committed to providing financing if and when necessary to fund the Company’s estimated $100,000 cash operating expenses for the year ended August 31, 2019. Basis of Presentation, Measurement and Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with the Company’s audited financial statements for the years ended August 31, 2018 and 2017 and their accompanying notes. The accompanying unaudited condensed consolidated financial statements are expressed in Canadian Dollars (“CAD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the six months ended February 28, 2019 are not necessarily indicative of the results that may be expected for the year ending August 31, 2019. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Significant intercompany accounts and transactions have been eliminated.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Feb. 28, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements include the financial statements of the Company, TSI, Notox, 1894632 Ontario Inc. (“Subco”), and 1894631 Ontario Inc., the Company’s subsidiaries. All significant inter-company balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to equipment, fair values of intangible assets, useful lives of intangible assets and the likelihood of realization of its deferred tax assets . Fair Value of Financial Instruments Carrying values of cash, accounts payable and accrued liabilities, advances from related parties/shareholders, license assignment fee and accrued interest payable and stock subscribed approximate fair value because of the short-term nature of these items. Amounts receivable consists primarily of Harmonized Sales Tax (“HST”) receivable from the Government of Canada. HST is not a financial instrument.

Reverse Takeover

Reverse Takeover	6 Months Ended
	Feb. 28, 2019
Business Combinations [Abstract]
Reverse Takeover	3. Reverse Takeover On June 28, 2013 (the “Closing Date”), the Company, its wholly-owned subsidiary Subco and TSI entered into a share exchange agreement (the “Exchange Agreement”) with certain of the shareholders of TSI (the “Selling Shareholders”) pursuant to which the Company acquired 39,015,439 common shares, or approximately 78% of the issued and outstanding shares, of TSI in exchange for the issuance of 39,015,439 preferred shares of Subco to the Selling Shareholders on a one-for-one basis. Each one preferred share of Subco is exchangeable into one share of the Company’s common stock at the option of the holder subject to certain restrictions. On February 17, 2015, the Company, Subco, TSI and the Selling Shareholders entered into an amendment to the Exchange Agreement in order to correct certain administrative errors in the Exchange Agreement and provide for the post-closing execution of the Exchange Agreement by those shareholders of TSI who were not original signatories thereto. In addition, the Selling Shareholders approved certain changes to the rights, privileges, restrictions and conditions attached to the preferred shares of Subco by consent in writing. This included extending the automatic expiration date in respect of the preferred shares of Subco from June 30, 2015 to June 30, 2017. On February 22, 2017, this automatic expiration date was further extended to December 31, 2018, and on December 27, 2018, this date was further extended to December 31, 2020.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Feb. 28, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3 – Unobservable inputs that are supported by little or no market activity, which require management judgment or estimation. The Company measures its financial instruments at fair value. The carrying value of cash deposits is a reasonable estimate of its fair value due to the short maturity of the financial instrument. The Company’s stock purchase warrants are measured at fair value on a recurring basis.

License Agreement, Net

License Agreement, Net	6 Months Ended
	Feb. 28, 2019
Finite-Lived Intangible Assets, Net [Abstract]
License Agreement, Net	5. License Agreement, Net On December 1, 2012, Zoran Holding Corporation (“ZHC”) and the Clinic entered into the License Agreement whereby the Clinic granted ZHC an exclusive worldwide license and a non-exclusive worldwide license in the field of aesthetics and pain to make, use, offer to sell, sell and import certain products throughout the term of the License Agreement. Royalties and other payments are payable quarterly. Notox is required to achieve two commercial milestones: regulatory filings submitted to regulatory authorities by November 30, 2019 and first commercial sale within nine months following regulatory approval. Failure to achieve these milestones, without satisfactory justification, constitutes a material breach of the License Agreement giving the Clinic the right, but not the obligation, to convert the License Agreement to a non-exclusive license or terminate the License Agreement. The Clinic has the right to verify Notox’s compliance with the License Agreement. Within 30 days following Notox’s receipt of the first regulatory approval, Notox is required to reimburse the Clinic for current patenting costs. All patenting costs, patent office fees and outside patent counsel costs will, at the Clinic’s option, either be paid directly by Notox or by the Clinic with the Clinic invoicing Notox, provided that Notox has no obligation to pay or reimburse the Clinic until after first regulatory approval has been obtained. Upon termination or expiration of the License Agreement, all accrued and unreimbursed patenting costs become immediately due and payable to the Clinic. As of February 28, 2019, all accrued and unreimbursed patenting costs totaled $237,341 (August 31, 2018 - $227,707). Pursuant to above, the fair value and gross carrying value of the License Agreement is as follows: License Agreement $ 133,212 Cash 131 Accrued liabilities (5,423 ) Capital stock exchanged (50,000,000 shares at US$0.002 per share) $ 127,920 Fair value of License Agreement $ 133,212 Acquisition costs 19,519 Assignment fee (US$1,000,000) 1,347,000 Gross carrying value of License Agreement $ 1,499,731 February 28, 2019 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 468,665 $ 1,031,066 August 31, 2018 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 374,932 $ 1,124,799 As of February 28, 2019, amortization expense on the License Agreement for the next six years was expected to be as follows: Amount Year ending: 2019 $ 93,733 2020 187,466 2021 187,466 2022 187,466 2023 187,466 2024 187,469 Total $ 1,031,066

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	6 Months Ended
	Feb. 28, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	6. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of: February 28, 2019 August 31, 2018 Trade payables $ 1,728,941 $ 1,412,277 Vendor accruals 147,929 170,414 Accounts payable and accrued liabilities $ 1,876,870 $ 1,582,691

Related Party Transactions and

Related Party Transactions and Balances	6 Months Ended
	Feb. 28, 2019
Related Party Transactions [Abstract]
Related Party Transactions and Balances	7. Related Party Transactions and balances All transactions with related parties occurred in the normal course of business and were measured at the exchange amount, which was the amount of consideration agreed upon between management and the related parties. Following are the related party balances and transactions: a) Related party balances Advances from related parties include: ● At February 28, 2019, the Company owed $232,000 (August 31, 2018 - $232,000) in advances payable to the President of the Company. These advances are unsecured and bear interest at 3% per annum. Accrued interest payable to the President totaled $36,629 at February 28, 2019 (August 31, 2018 - $32,538). ● At February 28, 2019, the Company owed $102,837 (August 31, 2018 - $51,000) in advances payable to the CEO of the Company. This balance bears no interest and has no repayment terms. Accounts payable and accrued liabilities include: ● At February 28, 2019, the Company owed $1,185,624 (August 31, 2018 - $1,090,187) in consulting fees to the President, CEO, and former CFO of the Company. b) Related party transactions During the six months ended February 28, 2019, the Company had the following transactions with related parties: ● Consulting fees expense of $81,765 (six months ended February 28, 2018 - $157,178) in connection with the services provided by the companies controlled by the President and CEO of the Company. ● Interest expense of $5,534 (six months ended February 28, 2018 - $761) in connection with advances owing to the President and other shareholders of the Company. ● The CEO of the Company advanced $28,836 (six months ended February 28, 2018 - $46,000). These advances are unsecured, bear no interest and have no repayment terms.

Advances from Shareholders

Advances from Shareholders	6 Months Ended
	Feb. 28, 2019
Related Party Transactions [Abstract]
Advances from Shareholders	8. Advances from Shareholders Advances payable to shareholders totaled $145,000 at February 28, 2019 (August 31, 2018 - $145,000) These advances are unsecured and bear interest at 3% per annum, with no specific repayment terms. Interest expense of $2,157 was incurred on these advances during the six months ended February 28, 2019 (six months ended February 28, 2018 - $2,157). Accrued interest payable to shareholders totaled $19,128 at February 28, 2019 (August 31, 2018 - $16,971).

License Assignment Fee Payable

License Assignment Fee Payable	6 Months Ended
	Feb. 28, 2019
Finite-Lived Intangible Assets, Net [Abstract]
License Assignment Fee Payable	9. License Assignment Fee Payable Pursuant to the amendment to the Share Exchange Agreement, the Company will pay an aggregate of US$1,000,000 to Zoran K Corporation, a private Ontario corporation (“ZKC”), in the form of a one-time assignment fee. The assignment fee payable is repayable in monthly instalments of US$50,000 beginning on October 1, 2016. Upon completion of any equity financing pursuant to which the Company raises gross proceeds of at least US$1,000,000, the outstanding balance is to be repaid in full. Since September 1, 2017, interest of 24% per annum, compounding annually, has been accrued on the outstanding balance payable. Interest expense of $281,032 was accrued on the balance payable during the six months ended February 28, 2019. At February 28, 2019, the balance of the license assignment fee payable and interest payable to ZKC was $1,000,758 (August 31, 2018 - $882,257). See Note 5.

Commitments

Commitments	6 Months Ended
	Feb. 28, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments	10. Commitments On December 1, 2015, the Company entered into consulting agreements with 1040614 Ontario Ltd., a private Ontario corporation (the “Old 1040614 Agreement”), and MCM Consulting, an Ontario sole proprietorship (the “Old MCM Agreement”, and together with the Old 1040614 Agreement, the “Old Agreements”). Pursuant to the Old 1040614 Agreement, 1040614 Ontario Ltd. (“1040614”), through its principal, performed various services related to business development, strategic planning and capital-raising for the Company. Pursuant to the Old MCM Agreement, the sole proprietor of MCM Consulting (“MCM”) acted in the capacity of CEO of the Company. On June 13, 2016, the Old 1040614 and MCM Agreements were terminated and replaced by the 1040614 and MCM Agreements (see below). As at February 28, 2019, 1040614 and MCM are each entitled to $80,770 (August 31, 2018 - $80,770) in accrued remuneration in respect of the Old Agreements. On June 13, 2016, the Company entered into consulting agreements with 1040614 (the “1040614 Agreement”), MCM (the “MCM Agreement”) and ZKC (the “ZKC Agreement”). Pursuant to the 1040614 Agreement, 1040614, through its principal, performs general consulting services on behalf of the Company. Pursuant to the MCM Agreement, the sole proprietor of MCM acts in the capacity of President of the Company. Pursuant to the ZKC Agreement, ZKC, through its principal, acts in the capacity of CEO of the Company. Each consulting agreement is for a period of 10 years, with successive automatic renewal periods of two years until terminated. Pursuant to these consulting agreements, each consultant is entitled to receive the following compensation: ● Remuneration – an aggregate of US$125,000 per annum plus HST on a bi-monthly basis; ● EPS Bonus – when the Company generates earnings per share of $0.05, plus any multiple thereof, the Company shall issue the consultant 1,000,000 shares of the Company’s common stock and pay the consultant US$250,000 plus HST; ● Change of Control Bonus – immediately prior to the completion of a change of control (as defined in these consulting agreements) the Company shall issue the consultant an aggregate of 20,000,000 shares of the Company’s common stock; and ● Additional Bonus – the company may from time to time pay the consultant one or more bonuses as determined by the Board of Directors at its sole discretion. Effective February 3, 2018, the Company terminated the 1040614 Agreement. On August 31, 2018, the Company renewed its premises lease for another year beginning on September 1, 2018 for a rental of $21,000 for the year plus HST.

Stockholders' Deficiency

Stockholders' Deficiency	6 Months Ended
	Feb. 28, 2019
Equity [Abstract]
Stockholders' Deficiency	11. Stockholders’ Deficiency Authorized stock As at February 28, 2019, the Company was authorized to issue 500,000,000 (August 31, 2018 - 300,000,000) shares of common stock at a par value of US$0.001. On October 9, 2018, the Company’s shareholders and directors approved a change of the Company’s name from Tropic International Inc. to Notox Technologies Corp. and an increase in the Company’s authorized common stock to 500,000,000 shares. The name change and authorized common stock increase were effected on November 19, 2018. At February 28, 2019, the Company had 57,532,843 shares of common stock legally issued and outstanding (August 31, 2018 - 57,532,843). Share issuances During the six months ended February 28, 2018, the Company completed the following common stock transactions: ● On September 21, 2017, the Company closed a US dollar financing pursuant to which the Company issued 630,000 units at US$1.00 per unit for gross proceeds of $830,674, with each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of common stock exercisable at a price of US$1.40 per share until September 7, 2019. $491,041 was allocated to common stock and $339,633 was allocated to stock purchase warrants. The Company paid cash finder’s fees of $6,435 and issued 5,000 finder’s stock purchase warrants exercisable at US$1.40 per warrant share until July 17, 2019, valued at $2,581 and credited to stock purchase warrants. ● On September 21, 2017, the Company issued 10,000 shares of common stock at $0.80 per share for gross proceeds of $8,000 pursuant to the exercise of warrants during the year ended August 31, 2017. $2,049 of the gross proceeds received that was allocated to these warrants has been deducted from additional paid-in capital. There were no share issuances during the six months ended February 28, 2019. Shares to be issued Common stock to be issued of 98,750 shares ($119,890) is comprised of 18,750 shares to be issued from the exercise of warrants (as explained below), and 80,000 shares to be issued from private placements as detailed below: ● On February 25, 2019, the Company has to issue 15,000 shares of common stock through a private placement with a fair value of $19,311 at a rate of U$1.29 per share. ● On February 28, 2019, the Company has to issue 65,000 shares of common stock through a private placement with a fair value of $85,579 at a rate of $1.32 per share. Warrant exercises During the six months ended February 28, 2019, the Company completed the following warrants transactions: ● On November 27, 2018, the Company issued 12,500 shares of common stock at $0.80 per share for gross proceeds of $10,000 pursuant to the exercise of warrants. ● As of February 28, 2019, the Company has to issue.6,250 shares of common stock at $0.80 per share for gross proceeds of $5,000 pursuant to the exercise of warrants during the period ended February 28, 2019. Stock Purchase Warrants The continuity of Canadian dollar denominated stock purchase warrants for the six months ended February 28, 2019 is as follows: Expiry Date Price August 31, 2017 Issued Expired August 31, 2018 Issued Expired February 28, 2019 October 31, 2018 $ 0.80 130,000 — (12,500 ) 117,500 — (117,500 ) — At February 28, 2019, the weighted-average remaining contractual life of Canadian dollar warrants outstanding was 0.00 years (August 31, 2018 - 0.17). The continuity of US dollar denominated stock purchase warrants for the six months ended February 28, 2019 is as follows: Expiry Date Price August 31, 2017 Issued August 31, 2018 Issued Expired February 28, 2019 September 30, 2018 – Finder US$1.40 15,000 — 15,000 — (15,000 ) — October 31, 2018 US$0.80 220,770 — 220,770 — (220,770 ) — November 2, 2018 US$1.40 400,000 — 400,000 — (400,000 ) — July 17, 2019 – Finder US$1.40 — 5,000 5,000 — — 5,000 September 7, 2019 US$1.40 — 630,000 630,000 — — 630,000 635,770 635,000 1,270,770 — (635,770 ) 635,000 At February 28, 2019, the weighted-average remaining contractual life of US dollar warrants outstanding was 0.52 years (August 31, 2018 – 0.59 years). The Company used the Black-Scholes Option Pricing Model to determine the fair values of unit warrants and finder’s warrants issued pursuant to private placements during the years ended August 31, 2018 and 2017 with the following assumptions: February 28, 2019 August 31, 2018 Expected dividend yield 0.00 % 0.00 % Risk-free interest rate 1.78 % 1.47% - 2.04 % Expected stock price volatility 100.00 % 100.00 % Expected life of warrants 0.63 – 0.77 years 0.08 – 2 years

Risks and Uncertainties

Risks and Uncertainties	6 Months Ended
	Feb. 28, 2019
Risks and Uncertainties [Abstract]
Risks and Uncertainties	12. Risks and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect its future operating results and cause actual results to vary materially from expectations include, but are not limited to: current economic conditions; the Company’s degree of success in securing regulatory approval and marketing products developed pursuant to the License Agreement; increasing competition; and dependence on its existing management and key personnel.

Accounting Pronouncements

Accounting Pronouncements	6 Months Ended
	Feb. 28, 2019
Accounting Changes and Error Corrections [Abstract]
Accounting Pronouncements	13. Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company will be evaluating the impact this standard will have on the Company’s financial statements. In June 2018, the FASB issued ASU 2018-07 to expand the scope of ASC Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently in the process of evaluating the effects of this pronouncement on the consolidated financial statements, including potential early adoption. In November 2017, the FASB issued ASU 2017-14 amending ASC Topic 605, which states the required steps to achieve the core principle that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted this pronouncement on a modified retrospective basis. On April 1, 2018, the Company adopted ASU 2017-14 to clarify existing guidance on revenue recognition. In November 2016, the FASB issued ASU 2016-18 addressing the treatment of restricted cash equivalents in ASC Topic 230. This guidance requires entities to show changes in the total of cash, cash equivalents and restricted cash in the combined statement of cash flows. On January 1, 2018, the Company adopted ASU 2016-18 to clarify how entities should present restricted cash and restricted cash equivalents in the statement of cash flows. This guidance was adopted on a retrospective basis, and such adoption did not have a material impact on the Company’s combined financial position and/or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This guidance revises the accounting related to leases by requiring lessees to recognize a lease liability and a right-of-use asset for all leases. The new lease guidance also simplifies the accounting for sale and leaseback transactions. This ASU is effective for annual reporting periods beginning after December 15, 2018 and early adoption is permitted. The Company does not believe the guidance will have a material impact on its consolidated financial statements.

Subsequent Events

Subsequent Events	6 Months Ended
	Feb. 28, 2019
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Event The Company’s management has evaluated subsequent events up to April 19, 2019, the date the accompanying condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined that there have been no events that have occurred that would require adjustments to the disclosures in the financial statements .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Feb. 28, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the financial statements of the Company, TSI, Notox, 1894632 Ontario Inc. (“Subco”), and 1894631 Ontario Inc., the Company’s subsidiaries. All significant inter-company balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to equipment, fair values of intangible assets, useful lives of intangible assets and the likelihood of realization of its deferred tax assets .
Fair Value of Financial Instruments	Fair Value of Financial Instruments Carrying values of cash, accounts payable and accrued liabilities, advances from related parties/shareholders, license assignment fee and accrued interest payable and stock subscribed approximate fair value because of the short-term nature of these items. Amounts receivable consists primarily of Harmonized Sales Tax (“HST”) receivable from the Government of Canada. HST is not a financial instrument.

License Agreement, Net (Tables)

License Agreement, Net (Tables)	6 Months Ended
	Feb. 28, 2019
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Fair Value and Carrying Value of License Agreement	Pursuant to above, the fair value and gross carrying value of the License Agreement is as follows: License Agreement $ 133,212 Cash 131 Accrued liabilities (5,423 ) Capital stock exchanged (50,000,000 shares at US$0.002 per share) $ 127,920 Fair value of License Agreement $ 133,212 Acquisition costs 19,519 Assignment fee (US$1,000,000) 1,347,000 Gross carrying value of License Agreement $ 1,499,731
Schedule of License Agreement	February 28, 2019 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 468,665 $ 1,031,066 August 31, 2018 Gross carrying amount Accumulated amortization Net carrying amount License Agreement $ 1,499,731 $ 374,932 $ 1,124,799
Schedule of Amortization Expense on Intangible Assets	As of February 28, 2019, amortization expense on the License Agreement for the next six years was expected to be as follows: Amount Year ending: 2019 $ 93,733 2020 187,466 2021 187,466 2022 187,466 2023 187,466 2024 187,469 Total $ 1,031,066

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Feb. 28, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accounts payable and accrued liabilities consisted of: February 28, 2019 August 31, 2018 Trade payables $ 1,728,941 $ 1,412,277 Vendor accruals 147,929 170,414 Accounts payable and accrued liabilities $ 1,876,870 $ 1,582,691

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	6 Months Ended
	Feb. 28, 2019
Equity [Abstract]
Schedule of Stock Purchase Warrants	The continuity of Canadian dollar denominated stock purchase warrants for the six months ended February 28, 2019 is as follows: Expiry Date Price August 31, 2017 Issued Expired August 31, 2018 Issued Expired February 28, 2019 October 31, 2018 $ 0.80 130,000 — (12,500 ) 117,500 — (117,500 ) — The continuity of US dollar denominated stock purchase warrants for the six months ended February 28, 2019 is as follows: Expiry Date Price August 31, 2017 Issued August 31, 2018 Issued Expired February 28, 2019 September 30, 2018 – Finder US$1.40 15,000 — 15,000 — (15,000 ) — October 31, 2018 US$0.80 220,770 — 220,770 — (220,770 ) — November 2, 2018 US$1.40 400,000 — 400,000 — (400,000 ) — July 17, 2019 – Finder US$1.40 — 5,000 5,000 — — 5,000 September 7, 2019 US$1.40 — 630,000 630,000 — — 630,000 635,770 635,000 1,270,770 — (635,770 ) 635,000
Schedule of Stock Options Valuation Assumptions	The Company used the Black-Scholes Option Pricing Model to determine the fair values of unit warrants and finder’s warrants issued pursuant to private placements during the years ended August 31, 2018 and 2017 with the following assumptions: February 28, 2019 August 31, 2018 Expected dividend yield 0.00 % 0.00 % Risk-free interest rate 1.78 % 1.47% - 2.04 % Expected stock price volatility 100.00 % 100.00 % Expected life of warrants 0.63 – 0.77 years 0.08 – 2 years

Company Overview and Basis of_2

Company Overview and Basis of Presentation (Details Narrative) - CAD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018	Feb. 28, 2019	Feb. 28, 2018	Nov. 30, 2018	Aug. 31, 2018	Nov. 30, 2017	Aug. 31, 2017	Jun. 13, 2016
Accumulated deficit	$ (12,249,108)		$ (12,249,108)			$ (11,783,486)
Working capital deficiency	3,446,326		3,446,326			3,203,961
Stockholders' equity	(2,652,597)	$ (1,859,389)	(2,652,597)	$ (1,859,389)	$ (2,419,997)	(2,306,865)	$ (1,713,130)	$ (1,986,065)
Operating expenses	46,866	$ 59,336	101,546	108,483
Cash liabilities	3,443,360		3,443,360			2,942,000
Accounts payable and accrued liabilities	1,876,870		1,876,870
Advances from related parties/shareholders	565,732		565,732			477,509
License assignment fee and accrued interest payable	$ 1,000,758		1,000,758			$ 882,257
Net cash used in operating activities			(100,459)	$ (72,460)
August 31, 2019 [Member]
Net cash used in operating activities			$ 100,000
Notox Bioscience Inc [Member]
Purpose of acquiring right percentage									100.00%

Reverse Takeover (Details Narra

Reverse Takeover (Details Narrative) - shares	Feb. 22, 2017	Jun. 28, 2013
Exchange Agreement [Member]
Agreement expiration, description	On February 22, 2017, this automatic expiration date was further extended to December 31, 2018, and on December 27, 2018, this date was further extended to December 31, 2020.
Tropic Spa Inc [Member] | Common Stock [Member]
Common shares acquired		39,015,439
Percentage of shares exchange for preferred stock of holding company		78.00%
Subco [Member] | Preferred Stock [Member]
Number of preferred stock for exchange		39,015,439

License Agreement, Net (Details

License Agreement, Net (Details Narrative) - CAD ($)	Feb. 28, 2019	Aug. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Accrued and unreimbursed patenting costs	$ 237,341	$ 227,707

License Agreement, Net - Schedu

License Agreement, Net - Schedule of Fair Value and Carrying Value of License Agreement (Details) - License Agreement [Member]	Feb. 28, 2019CAD ($)
License Agreement	$ 133,212
Cash	131
Accrued liabilities	(5,423)
Capital stock exchanged (50,000,000 shares at US$0.002 per share)	127,920
Fair value of License Agreement	133,212
Acquisition costs	19,519
Assignment fee (US$1,000,000)	1,347,000
Gross carrying value of License Agreement	$ 1,499,731

License Agreement, Net - Sche_2

License Agreement, Net - Schedule of Fair Value and Carrying Value of License Agreement (Details) (Parenthetical) - CAD ($)	6 Months Ended
	Feb. 28, 2019	Aug. 31, 2018
Number of shares exchanged
License assignment fee payable	$ 1,000,758	$ 882,257
License Agreement [Member]
Number of shares exchanged	50,000,000
Exchanges share, per share value	$ 0.002
License assignment fee payable	$ 1,000,000

License Agreement, Net - Sche_3

License Agreement, Net - Schedule of License Agreement (Details) - CAD ($)	Feb. 28, 2019	Aug. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
License Agreement, Gross carrying amount	$ 1,499,731	$ 1,499,731
License Agreement, Accumulated amortization	468,665	374,932
License Agreement, Net carrying amount	$ 1,031,066	$ 1,124,799

License Agreement, Net - Sche_4

License Agreement, Net - Schedule of Amortization Expense on Intangible Assets (Details) - License Agreement [Member]	Feb. 28, 2019CAD ($)
2019	$ 93,733
2020	187,466
2020	187,466
2022	187,466
2023	187,466
2024	187,469
Total	$ 1,031,066

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - CAD ($)	Feb. 28, 2019	Aug. 31, 2018
Payables and Accruals [Abstract]
Trade payables	$ 1,728,941	$ 1,412,277
Vendor accruals	147,929	170,414
Accounts payable and accrued liabilities	$ 1,876,870	$ 1,582,691

Related Party Transactions an_2

Related Party Transactions and Balances (Details Narrative) - CAD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018	Feb. 28, 2019	Feb. 28, 2018	Aug. 31, 2018
Unsecured bear interest rate	3.00%		3.00%
Consulting fees	$ 11,854	$ 13,000	$ 32,334	$ 29,396
Advances from related parties/shareholders			88,223	46,000
President [Member]
Advances payable to related parties	232,000		232,000		$ 232,000
Interest payable to related parties	36,629		36,629		32,538
Chief Executive Officer [Member]
Advances payable to related parties	102,837		102,837		51,000
Advances from related parties/shareholders			28,836	46,000
President, CEO, and Former CFO [Member]
Accounts payable and accrued liabilities related parties	$ 1,185,624		1,185,624		$ 1,090,187
President, and CEO [Member]
Consulting fees			81,765	157,178
President and Other Shareholders [Member]
Interest expense			$ 5,534	$ 761

Advances from Shareholders (Det

Advances from Shareholders (Details Narrative) - CAD ($)	6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018	Aug. 31, 2018
Unsecured bear interest rate	3.00%
Shareholder [Member]
Advances payable to shareholders	$ 145,000		$ 145,000
Unsecured bear interest rate	3.00%
Interest expense	$ 2,157	$ 2,157
Accrued interest payable to shareholders	$ 19,128		$ 16,971

License Assignment Fee Payable

License Assignment Fee Payable (Details Narrative)	Oct. 01, 2016USD ($)	Feb. 28, 2019CAD ($)	Feb. 28, 2019USD ($)	Feb. 28, 2019USD ($)	Aug. 31, 2018CAD ($)
License assignment fee payable		$ 1,000,758			$ 882,257
Debt interest rate		3.00%		3.00%
Zoran K Corporation [Member]
License assignment fee payable		$ 1,000,758			$ 882,257
Share Exchange Agreement [Member] | Zoran K Corporation [Member]
Debt interest rate		24.00%		24.00%
Interest expense		$ 281,032
Share Exchange Agreement [Member] | Zoran K Corporation [Member] | USD Currency [Member]
License assignment fee payable				$ 1,000,000
Debt periodic payment	$ 50,000
Gross proceeds from sale of stock			$ 1,000,000

Commitments (Details Narrative)

Commitments (Details Narrative)	Jun. 13, 2016$ / shares	Jun. 13, 2016USD ($)shares	Feb. 28, 2019CAD ($)	Feb. 28, 2018CAD ($)	Feb. 28, 2019CAD ($)	Feb. 28, 2018CAD ($)	Aug. 31, 2018CAD ($)
Premises lease rental			$ 5,530	$ 7,439	$ 10,780	$ 13,139
Premises Lease [Member]
Premises lease rental					21,000
Consultant [Member]
Share issued during period | shares		1,000,000
Consultant [Member] | USD Currency [Member]
Share issued during period, value		$ 250,000
MCM Agreement [Member]
Accrued remuneration			$ 80,770		$ 80,770		$ 80,770
Consulting Agreement [Member] | Consultant [Member]
Consulting agreement period		10 years
Earnings per share | $ / shares	$ 0.05
Share issued during period | shares		20,000,000
Consulting Agreement [Member] | Consultant [Member] | USD Currency [Member]
Remuneration		$ 125,000

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative)	Feb. 28, 2019CAD ($)$ / sharesshares	Feb. 28, 2019CAD ($)$ / sharesshares	Feb. 25, 2019CAD ($)$ / sharesshares	Nov. 27, 2018CAD ($)$ / sharesshares	Sep. 21, 2017CAD ($)$ / sharesshares	Feb. 28, 2019CAD ($)$ / sharesshares	Feb. 28, 2019CAD ($)$ / sharesshares	Feb. 28, 2018CAD ($)	Aug. 31, 2018shares	Aug. 31, 2017CAD ($)	Feb. 28, 2019$ / sharesshares	Sep. 21, 2017$ / shares
Common stock, shares authorized | shares	500,000,000	500,000,000				500,000,000	500,000,000		300,000,000		500,000,000
Common stock, shares issued | shares	57,532,843	57,532,843				57,532,843	57,532,843		57,532,843		57,532,843
Common stock, shares outstanding | shares	57,532,843	57,532,843				57,532,843	57,532,843		57,532,843		57,532,843
Common stock shares issued during period | shares
Proceeds from issuance of common stock | $						$ 104,890
Proceeds from exercise of warrants | $							$ 5,000
Private Placement [Member]
Common stock shares issued during period | shares	65,000		15,000				80,000
Shares issued price per share | $ / shares	$ 1.32	$ 1.32	$ 1.29			$ 1.32	$ 1.32
Proceeds from issuance of common stock | $	$ 85,579		$ 19,311
Common Stock [Member]
Common stock shares issued during period | shares					630,000		5,000
Proceeds from issuance of common stock | $					$ 830,674					$ 8,000
Warrant to purchase, shares | shares					1
Common stock allocated value | $					$ 491,041
Share purchase warrants allocated value | $					$ 339,633
Finder's fees | $							$ 6,435
Purchase warrant, value | $							$ 2,581
Proceeds from exercise of warrants | $										$ 2,049
Common Stock One [Member]
Common stock shares issued during period | shares					10,000
Shares issued price per share | $ / shares					$ 0.80
Shared to be Issued [Member]
Common stock shares issued during period | shares							98,750
Proceeds from issuance of common stock | $						$ 104,890	$ (119,890)
Warrant to purchase, shares | shares	18,750	18,750				18,750	18,750				18,750
Warrant [Member]
Common stock shares issued during period | shares		6,250		12,500
Shares issued price per share | $ / shares	$ 0.80	$ 0.80		$ 0.80		$ 0.80	$ 0.80
Proceeds from issuance of common stock | $		$ 5,000		$ 10,000
Warrants outstanding of weighted-average remaining contractual life							0 years		2 months 1 day
USD Currency [Member]
Common stock, par share value | $ / shares											$ 0.001
USD Currency [Member] | Common Stock [Member]
Shares issued price per share | $ / shares												$ 1
Warrants exercise price per share | $ / shares												$ 1.40
USD Currency [Member] | Warrant [Member]
Warrants outstanding of weighted-average remaining contractual life							6 months 7 days		7 months 2 days

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Stock Purchase Warrants (Details)	6 Months Ended	12 Months Ended
	Feb. 28, 2019$ / sharesshares	Aug. 31, 2018shares	Feb. 28, 2019$ / shares
Stock purchase warrants, beginning	1,270,770	635,770
Stock purchase warrants, issued		635,000
Stock purchase warrants, expired	(635,770)
Stock purchase warrants, ending	635,000	1,270,770
October 31, 2018 [Member]
Stock purchase warrants price per share | $ / shares	$ 0.80
Stock purchase warrants, beginning	117,500	130,000
Stock purchase warrants, issued
Stock purchase warrants, expired	(117,500)	(12,500)
Stock purchase warrants, ending		117,500
October 31, 2018 [Member] | USD Currency [Member]
Stock purchase warrants price per share | $ / shares			$ 0.80
Stock purchase warrants, beginning	220,770	220,770
Stock purchase warrants, issued
Stock purchase warrants, expired	(220,770)
Stock purchase warrants, ending		220,770
September 30, 2018 - Finder [Member] | USD Currency [Member]
Stock purchase warrants price per share | $ / shares			1.40
Stock purchase warrants, beginning	15,000	15,000
Stock purchase warrants, issued
Stock purchase warrants, expired	(15,000)
Stock purchase warrants, ending		15,000
November 2, 2018 [Member] | USD Currency [Member]
Stock purchase warrants price per share | $ / shares			1.40
Stock purchase warrants, beginning	400,000	400,000
Stock purchase warrants, issued
Stock purchase warrants, expired	(400,000)
Stock purchase warrants, ending		400,000
July 17, 2019 - Finder [Member] | USD Currency [Member]
Stock purchase warrants price per share | $ / shares			1.40
Stock purchase warrants, beginning	5,000
Stock purchase warrants, issued		5,000
Stock purchase warrants, expired
Stock purchase warrants, ending		5,000
September 7, 2019 | USD Currency [Member]
Stock purchase warrants price per share | $ / shares			$ 1.40
Stock purchase warrants, beginning	630,000
Stock purchase warrants, issued		630,000
Stock purchase warrants, expired
Stock purchase warrants, ending		630,000

Stockholders' Deficiency - Sc_2

Stockholders' Deficiency - Schedule of Stock Options Valuation Assumptions (Details) - Warrant [Member]	6 Months Ended	12 Months Ended
	Feb. 28, 2019	Aug. 31, 2018
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.78%
Expected stock price volatility	100.00%	100.00%
Minimum [Member]
Risk-free interest rate		1.47%
Expected life of warrants	7 months 17 days	29 days
Maximum [Member]
Risk-free interest rate		2.04%
Expected life of warrants	9 months 7 days	2 years